文献速递肝病

慢性乙型肝炎患者换用替诺福韦艾拉酚胺后脊柱骨密度增加:一项前瞻性跨国研究

Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-10-26

这项前瞻性跨国研究纳入270例换用替诺福韦艾拉酚胺(TAF)的慢性乙型肝炎成人患者,评估24个月时病毒抑制、生化应答及肾脏/骨骼安全性。换药后24个月病毒抑制率从95.2%升至98.8%,脊柱T值从-1.43±1.36改善至-1.17±1.38,而eGFR无显著变化。

要点

  • 换用TAF后24个月病毒抑制率从95.2%升至98.8%(p=0.014)。
  • 脊柱T值从-1.43±1.36改善至-1.17±1.38(p<0.0001)。
  • eGFR从88.4±16.9变为89.5±16.3 mL/min/1.73 m²(p=0.13),无显著变化。

核心结论

  • 换用TAF后24个月,病毒抑制率和脊柱骨密度显著改善,肾功能保持稳定。

研究设计与样本

  • 前瞻性研究,在日本、韩国、台湾和美国的14个中心纳入270例换用TAF的慢性乙型肝炎成人患者。
  • 平均年龄58.1岁,男性占58.2%,肝硬化占12.2%,73.3%既往接受恩替卡韦单药治疗。

主要发现

  • 病毒抑制率从95.2%升至98.8%(p=0.014)。
  • 脊柱T值从-1.43±1.36改善至-1.17±1.38(p<0.0001)。
  • eGFR从88.4±16.9变为89.5±16.3 mL/min/1.73 m²(p=0.13),无显著变化。
  • 多因素分析中,男性与脊柱T值恶化风险较低显著相关(OR 0.29,p=0.020)。
  • 年龄与慢性肾脏病分期恶化风险较高显著相关(OR 1.07,p=0.019)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited. AIMS: To assess the treatment and renal/bone safety outcomes following the switch to TAF. METHODS: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T-scores (L-spine) by bone absorptiometry by 24 months after switch to TAF. RESULTS: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T-score improved significantly from -1.43 ± 1.36 to -1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9-89.5 ± 16.3 mL/min/1.73 m2 , p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T-score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T-score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019). CONCLUSIONS: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ogawa E, Jun DW, Toyoda H, et al. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study. Aliment Pharmacol Ther. 2023. PMID: 37882252. doi:10.1111/apt.17785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。